Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Cost of Revenue (2020 - 2022)

Immuneering (IMRX) has 3 years of Cost of Revenue data on record, last reported at $19343.0 in Q3 2022.

  • For Q3 2022, Cost of Revenue fell 91.17% year-over-year to $19343.0; the TTM value through Jun 2023 reached $19343.0, down 96.57%, while the annual FY2022 figure was $158122.0, 86.29% down from the prior year.
  • Cost of Revenue reached $19343.0 in Q3 2022 per IMRX's latest filing, down from $47933.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $409163.0 in Q1 2021 and bottomed at $19343.0 in Q3 2022.
  • Average Cost of Revenue over 3 years is $207028.8, with a median of $219088.0 recorded in 2021.
  • Peak YoY movement for Cost of Revenue: soared 34.4% in 2021, then plummeted 91.17% in 2022.
  • A 3-year view of Cost of Revenue shows it stood at $315002.0 in 2020, then crashed by 34.53% to $206221.0 in 2021, then tumbled by 90.62% to $19343.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $19343.0 in Q3 2022, $47933.0 in Q2 2022, and $90846.0 in Q1 2022.